Soleno Therapeutics, Inc. (SLNO)
Soleno Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Redwood City, CA, US. The stock last traded at $53.01, up 0.00% on the session, giving a market capitalisation of $2.76B. On trailing twelve-month figures it carries a trailing P/E of 27.09, a net margin of 33.7%. Its beta of -2.22 implies it has historically moved less than the broad market.
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
Soleno Therapeutics, Inc. is most often compared with the following Healthcare names: